Paid Clinical Trials Aberdeen
Discover 11 paid clinical trials in Aberdeen, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Observational StudyAvera Cancer Sequencing and Analytics Protocol (ASAP)
Sponsor:
Avera McKennan Hospital & University Health Center
Location:
Code:
NCT05142033
Conditions
Cancer
Cancer Diagnosis
Early Detection of Cancer
Breast Cancer
Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Telisotuzumab Vedotin vs. DocetaxelA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
AbbVie
Location:
Code:
NCT04928846
Conditions
Non Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Telisotuzumab Vedotin
Docetaxel
CamizestrantA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Sponsor:
AstraZeneca
Location:
Code:
NCT05774951
Conditions
Breast Cancer, Early Breast Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Camizestrant
Tamoxifen
Anastrozole
Letrozole
Exemestane
Drug CombinationsComparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT05561387
Conditions
Plasma Cell Myeloma
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Bortezomib
Daratumumab and Hyaluronidase-fihj
Dexamethasone
Lenalidomide
Quality-of-Life Assessment
Pembrolizumab & OlaparibTesting the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04548752
Conditions
Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy Procedure
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Olaparib
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Olaparib & BevacizumabTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Sponsor:
NRG Oncology
Location:
Code:
NCT06580314
Conditions
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube High Grade Serous Adenocarcinoma
FIGO Stage III Ovarian Cancer 2014
FIGO Stage IV Ovarian Cancer 2014
Ovarian Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Olaparib
ChemotherapyTesting the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT04340141
Conditions
Pancreatic Adenosquamous Carcinoma
Resectable Pancreatic Adenocarcinoma
Pancreatic Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Oxaliplatin
Irinotecan Hydrochloride
Leucovorin Calcium
Fluorouracil
Resection
OlaparibAPOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04858334
Conditions
Pancreatic Acinar Cell Carcinoma
Pancreatic Adenosquamous Carcinoma
Pancreatic Squamous Cell Carcinoma
Resectable Pancreatic Acinar Cell Carcinoma
Resectable Pancreatic Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Magnetic Resonance Imaging
Olaparib
Placebo Administration
Giredestrant vs. FulvestrantA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06065748
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Giredestrant
Fulvestrant
Abemaciclib
Palbociclib
Ribociclib
CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Sponsor:
AstraZeneca
Location:
Code:
NCT05952557
Conditions
Breast Cancer, Early Breast Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Camizestrant
Tamoxifen
Anastrozole
Letrozole
Exemestane